Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Rhea-AI Summary
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company, has announced a webcast presentation of initial Phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC. The webcast is scheduled for Monday, September 23, 2024, at 8:00 a.m. ET.
Black Diamond specializes in developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. The presentation will be accessible under the 'Events and Presentations' section of the company's website, with a replay available after the event.
Positive
- Reaching Phase 2 clinical trial stage for BDTX-1535
- Potential progress in treating recurrent EGFRm NSCLC
Negative
- None.
News Market Reaction – BDTX
On the day this news was published, BDTX declined 5.46%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Webcast to be held Monday, September 23, at 8:00 a.m. ET
CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET.
Webcast information
The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
For Media:
media@bdtx.com
FAQ
What is the date and time of Black Diamond Therapeutics' webcast for BDTX-1535 Phase 2 data?
What type of cancer is BDTX-1535 being tested for in the Phase 2 trial?
Where can investors access Black Diamond Therapeutics' (BDTX) webcast presentation?
What is Black Diamond Therapeutics' (BDTX) focus in oncology treatment?
